Updates in Hypertension and Cardiovascular Protection

Series editors:

Giuseppe Mancia Milan, Italy Enrico Agabiti Rosei Brescia, Italy The aim of this series is to provide informative updates on both the knowledge and the clinical management of a disease that, if uncontrolled, can very seriously damage the human body and is still among the leading causes of death worldwide. Although hypertension is associated mainly with cardiovascular, endocrine, and renal disorders, it is highly relevant to a wide range of medical specialties and fields – from family medicine to physiology, genetics, and pharmacology. The topics addressed by volumes in the series *Updates in Hypertension and Cardiovascular Protection* have been selected for their broad significance and will be of interest to all who are involved with this disease, whether residents, fellows, practitioners, or researchers.

More information about this series at http://www.springer.com/series/15049

Alberto Morganti • Enrico Agabiti Rosei Franco Mantero Editors

Secondary Hypertension





Editors
Alberto Morganti
Center of Clinical Physiology
and Hypertension, Policlinic Hospital
University of Milan
Milan
Italy

Franco Mantero Department of Medicine, Endocrine Unit University of Padua Padova Italy Enrico Agabiti Rosei Department of Clinical and Experimental Sciences University of Brescia Brescia Italy

ISSN 2366-4606 ISSN 2366-4614 (electronic) Updates in Hypertension and Cardiovascular Protection ISBN 978-3-030-45561-3 ISBN 978-3-030-45562-0 (eBook) https://doi.org/10.1007/978-3-030-45562-0

© Springer Nature Switzerland AG 2020

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland



Preface

It is common belief that secondary forms of hypertension are rare whereas in 95% of patients the cause of high blood pressure is unknown, which is said, euphemistically, "essential." Thus, many clinicians are reluctant to embark on expensive, timeconsuming, and potentially risky diagnostic procedures that most of the times turn out negative. However, there is increasing evidence from epidemiological studies that the prevalence of secondary hypertensions is much higher than previously thought accounting for 20–25% of all hypertensive patients, meaning that worldwide there are some 200 million people in whom the cause of high blood pressure is not recognized. There are additional, very good reasons for searching patients with secondary hypertension. First is that for equal blood pressure levels these patients are exposed to a greater risk of suffering major cardiovascular events than patients with essential hypertension and for this reason they require particular care. Second is that these patients are curable with appropriate interventions and liberated from the burden of a lifetime pharmacological therapy or, at least, have a chance to be treated with more specific and effective medications. Obviously for picking up patients with secondary hypertension, a good deal of clinical skill is required to appreciate the often vague and subtle symptoms and signs that characterize these individuals. A full comprehension of the mechanisms responsible for the development and maintenance of high blood pressure is also needed. This book was conceived to inform readers on the most updated advances in the epidemiological, pathophysiological, diagnostic, and therapeutic aspects of secondary hypertension provided by a group of the most respected European scholars in this field. We aim to offer an opportunity to expand readers' knowledge in an intricate area of cardiovascular medicine hoping that the new acquisitions may be translated to a better treatment of the many patients with secondary hypertension.

Milan, Italy Brescia, Italy Padova, Italy Alberto Morganti Enrico Agabiti Rosei Franco Mantero

Contents

Michel Burnier, Francesca Viazzi, Giovanna Leoncini, Grégoire Wuerzner, and Roberto Pontremoli
Atherosclerotic Renovascular Disease. 21 Peter W. de Leeuw and Costas Tsioufis
Fibromuscular Dysplasia: From a Rare Cause of Renovascular Hypertension to a More Frequent Systemic Arterial Disease
Primary Aldosteronism. 59 Gian Paolo Rossi
Familial Hyperaldosteronism. 79 Alessio Pecori, Silvia Monticone, Isabel Losano, Giovanni Cavaglià, Jacopo Pieroni, Franco Veglio, and Paolo Mulatero
Monogenic Forms of Hypertension 95 Filippo Ceccato and Franco Mantero
Pheochromocytoma and Paraganglioma
Hypertension in Cushing's Syndrome . 127 Filippo Ceccato, Mattia Barbot, Carla Scaroni, and Marco Boscaro
Vascular Disease
Obstructive Sleep Apnea 149 Joanna Kanarek-Kucner, Jacek Wolf, and Krzysztof Narkiewicz
Drug-Induced Hypertension

Hypertension in Acromegaly Peter Kamenický and Philippe Chanson	167
Organ Damage Enrico Agabiti Rosei, Damiano Rizzoni, Claudia Agabiti-Rosei, Anna Paini, and Maria Lorenza Muiesan	181
Secondary Hypertension and Cardiovascular Risk: An Overview	197